Fenofibrate but not fenofibric acid inhibits 11beta-hydroxysteroid dehydrogenase 1 in C2C12 myotubes

Molecular and Cellular Biochemistry

Volumn 344, Issue 1-2, 2010, Pages 91-98

  Kim, Chi Hyun ^a,b   Ramu, Ravirala ^a   Ahn, Jin Hee ^a   Bae, Myung Ae ^a   Cho, Young Sik ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

11Beta hydroxysteroid dehydrogenase 1; C2C12; Fenofibrate; Fenofibric acid; Homogeneous time resolved fluorescence cortisol assay; Peroxisome proliferator activated receptor alpha

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; FENOFIBRATE; FENOFIBRIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID;

ARTICLE; ENZYME ACTIVITY; MYOTUBE;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; CELL LINE; FENOFIBRATE; INHIBITORY CONCENTRATION 50; MICE; MUSCLES; PPAR ALPHA; PYRIMIDINES;

EID: 78449282141     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-010-0532-4     Document Type: Article

References (23)

1. T Dayspring G Pokrywka 2006 Fibrate therapy in patients with metabolic syndrome and diabetes mellitus Curr Atheroscler Rep 8 356 364 1:CAS:528:DC%2BD28Xpslagsrw%3D 10.1007/s11883-006-0032-x 16901405
2. N Latruffe M Cherkaoui Malki V Nicolas-Frances MC Clemencet B Jannin JP Berlot 2000 Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases Biochem Pharmacol 60 1027 1032 1:CAS:528:DC%2BD3cXmslOjsLo%3D 10.1016/S0006-2952(00)00416-0 11007938
3. A Hermanowski-Vosatka D Gerhold SS Mundt VA Loving M Lu Y Chen A Elbrecht M Wu T Doebber L Kelly D Milot Q Guo PR Wang M Ippolito YS Chao SD Wright R Thieringer 2000 PPARalpha agonists reduce 11beta-hydroxysteroid dehydrogenase type 1 in the liver Biochem Biophys Res Commun 279 330 336 1:CAS:528: DC%2BD3cXovVCntLo%3D 10.1006/bbrc.2000.3966 11118287
4. S Nakano Y Inada H Masuzaki T Tanaka S Yasue T Ishii N Arai K Ebihara K Hosoda K Maruyama Y Yamazaki N Shibata K Nakao 2007 Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes Am J Physiol Endocrinol Metab 292 E1213 E1222 1:CAS:528:DC%2BD2sXks1KjsLg%3D 10.1152/ajpendo.00340.2006 17190905
5. RA Srivastava 2009 Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists Eur J Pharmacol 607 258 263 1:CAS:528:DC%2BD1MXjsFWlsbY%3D 10.1016/j.ejphar.2009.02. 024 19245804
6. NZ Lu SE Wardell KL Burnstein D Defranco PJ Fuller V Giguere RB Hochberg L McKay JM Renoir NL Weigel EM Wilson DP McDonnell JA Cidlowski 2006 International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors Pharmacol Rev 58 782 797 1:CAS:528:DC%2BD2sXkt1aisQ%3D%3D 10.1124/pr.58.4.9 17132855
7. DN Brindley 1995 Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome Int J Obes Relat Metab Disord 19 Suppl 1 S69 S75 7550541
8. CB Whorwood SJ Donovan D Flanagan DI Phillips CD Byrne 2002 Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome Diabetes 51 1066 1075 1:CAS:528:DC%2BD38Xis1Oju7w%3D 10.2337/diabetes.51.4.1066 11916927
9. YS Cho CH Kim HG Cheon 2009 Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase 1 inhibitors Anal Biochem 392 110 116 1:CAS:528:DC%2BD1MXoslCksb0%3D 10.1016/j.ab.2009.04.038 19497289
10. TC Sandeep JL Yau AM MacLullich J Noble IJ Deary BR Walker JR Seckl 2004 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics Proc Natl Acad Sci USA 101 6734 6739 1:CAS:528:DC%2BD2cXjvVyhs7w%3D 10.1073/pnas.0306996101 15071189
11. K Kuwabara K Murakami M Todo T Aoki T Asaki M Murai J Yano 2004 A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1, 3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice J Pharmacol Exp Ther 309 970 977 1:CAS:528:DC%2BD2cXksFCnsbg%3D 10.1124/jpet.103.064659 14982965
12. K Shimomura H Shimizu M Ikeda S Okada M Kakei S Matsumoto M Mori 2004 Fenofibrate, troglitazone, and 15-deoxy-Delta12, 14-prostaglandin J2 close KATP channels and induce insulin secretion J Pharmacol Exp Ther 310 1273 1280 1:CAS:528:DC%2BD2cXnt1equ7s%3D 10.1124/jpet.104.067249 15201343
13. J Thomas KS Bramlett C Montrose P Foxworthy PI Eacho D McCann G Cao A Kiefer J McCowan KL Yu T Grese WW Chin TP Burris LF Michael 2003 A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha) versus liver X receptor J Biol Chem 278 2403 2410 1:CAS:528:DC%2BD3sXksFagug%3D%3D 10.1074/jbc.M209629200 12441342
14. NP Rath W Haq GK Balendiran 2005 Fenofibric acid Acta Crystallogr C 61 o81 o84 10.1107/S0108270104032573 15695917
15. J Caldwell 1989 The biochemical pharmacology of fenofibrate Cardiology 76 Suppl 1 33 41 10.1159/000174545 2713875 (discussion 41-44)
16. G Boden C Homko M Mozzoli M Zhang K Kresge P Cheung 2007 Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention Diabetes 56 248 255 1:CAS:528:DC%2BD2sXhtVWltLs%3D 10.2337/db06-0481 17192489
17. BA Hamelin J Turgeon 1998 Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors Trends Pharmacol Sci 19 26 37 1:CAS:528:DyaK1cXhtlChsr4%3D 10.1016/S0165-6147(97)01147- 4 9509899
18. JD Szustakowski JH Lee CA Marrese PA Kosinski NR Nirmala DM Kemp 2006 Identification of novel pathway regulation during myogenic differentiation Genomics 87 129 138 1:CAS:528:DC%2BD2MXhtlGgs7nP 10.1016/j.ygeno.2005.08.009 16300922
19. PM Potter RM Wadkins 2006 Carboxylesterases-detoxifying enzymes and targets for drug therapy Curr Med Chem 13 1045 1054 1:CAS:528: DC%2BD28XkslKqtLc%3D 10.2174/092986706776360969 16611083
20. P Li PS Callery LS Gan SK Balani 2007 Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction Drug Metab Dispos 35 1203 1208 1:CAS:528:DC%2BD2sXns1yhs7c%3D 10.1124/dmd.106.013904 17452418
21. D Khan JF Gilmer CG Carolan JM Gaynor SA Ryder 2008 Pharmacological effects of a novel isosorbide-based butyrylcholinesterase inhibitor Chem Biol Interact 175 231 234 1:CAS:528:DC%2BD1cXhtVygu77I 10.1016/j.cbi.2008.05.024 18606399
22. T Satoh M Hosokawa 1998 The mammalian carboxylesterases: from molecules to functions Annu Rev Pharmacol Toxicol 38 257 288 1:CAS:528:DyaK1cXivF2itLc%3D 10.1146/annurev.pharmtox.38.1.257 9597156
23. AS Kalgutkar BC Crews SW Rowlinson AB Marnett KR Kozak RP Remmel LJ Marnett 2000 Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors Proc Natl Acad Sci USA 97 925 930 1:CAS:528:DC%2BD3cXot1altA%3D%3D 10.1073/pnas.97.2.925 10639181